Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2

Adult Aged Aged, 80 and over Biomarkers, Tumor / genetics Clone Cells / metabolism Female Follow-Up Studies Genetic Association Studies Humans Leukemia, Myeloid, Acute / genetics Male Middle Aged Mutation Myelodysplastic Syndromes / genetics Myelodysplastic-Myeloproliferative Diseases / genetics Myeloproliferative Disorders / genetics Prognosis Prospective Studies Serine-Arginine Splicing Factors / genetics Survival Rate

Journal

Leukemia

ISSN: 1476-5551

Titre abrégé: Leukemia

Pays: England

ID NLM: 8704895

Informations de publication

Date de publication:
08 2021

Historique:

received: 07 02 2020

accepted: 27 11 2020

revised: 29 10 2020

pubmed: 23 12 2020

medline: 1 9 2021

entrez: 22 12 2020

Statut: ppublish

Résumé

Somatic mutations in splicing factor genes frequently occur in myeloid neoplasms. While SF3B1 mutations are associated with myelodysplastic syndromes (MDS) with ring sideroblasts, SRSF2

Identifiants

DOI: 10.1038/s41375-020-01106-z PMID: 33349666

pubmed: 33349666

doi: 10.1038/s41375-020-01106-z

pii: 10.1038/s41375-020-01106-z

doi:

Substances chimiques

Biomarkers, Tumor 0

SRSF2 protein, human 147153-65-9

Serine-Arginine Splicing Factors 170974-22-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

2371-2381

Informations de copyright

Références

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.

doi: 10.1056/NEJMoa1103283

Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478:64–69.

doi: 10.1038/nature10496

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

doi: 10.1182/blood-2009-03-209262

Shiozawa Y, Malcovati L, Gallì A, Sato-Otsubo A, Kataoka K, Sato Y, et al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nat Commun. 2018;9:3649.

doi: 10.1038/s41467-018-06063-x

Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SCW, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617–30.

doi: 10.1016/j.ccell.2015.04.006

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood. 2018;132:1225–40.

doi: 10.1182/blood-2018-04-843771

Saez B, Walter MJ, Graubert TA. Splicing factor gene mutations in hematologic malignancies. Blood. 2017;129:1260–9.

doi: 10.1182/blood-2016-10-692400

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jadersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–41.

doi: 10.1182/blood-2015-03-633537

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

doi: 10.1182/blood-2016-03-643544

Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Galli A, Della Porta MG, et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood. 2014;124:1513–21.

doi: 10.1182/blood-2014-03-560227

Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861–9.

doi: 10.1038/leu.2013.119

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.

doi: 10.1056/NEJMoa1516192

Smeets MF, Tan SY, Xu JJ, Anande G, Unnikrishnan A, Chalk AM, et al. Srsf2 P95H initiates myeloid bias and myelodysplastic/myeloproliferative syndrome from hemopoietic stem cells. Blood. 2018;132:608–21.

doi: 10.1182/blood-2018-04-845602

Kon A, Yamazaki S, Nannya Y, Kataoka K, Ota Y, Nakagawa MM, et al. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018;131:621–35.

doi: 10.1182/blood-2017-01-762393

Zhang J, Lieu YK, Ali AM, Penson A, Reggio KS, Rabadan R, et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci USA. 2015;112:E4726–E4734.

doi: 10.1073/pnas.1514105112

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011;118:6239–46.

doi: 10.1182/blood-2011-09-377275

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–64.

doi: 10.1182/blood-2013-03-492884

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

doi: 10.1182/blood-2016-08-733196

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

doi: 10.1182/blood-2012-03-420489

Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005–15.

doi: 10.1182/blood-2012-08-452938

Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.

doi: 10.1182/blood-2009-09-245837

Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, et al. Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer J. 2018;8. https://doi.org/10.1038/s41408-018-0152-x .

Karimi M, Nilsson C, Dimitriou M, Jansson M, Matsson H, Unneberg P, et al. High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia. Haematologica. 2015;100:e223–e225.

doi: 10.3324/haematol.2014.118034

Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A, et al. Gene expression and risk of leukemic transformation in myelodysplasia. Blood. 2017;130:2642–53.

doi: 10.1182/blood-2017-05-783050

Chen Y, Zhao L, Wang Y, Cao M, Gelowani V, Xu M, et al. SeqCNV: a novel method for identification of copy number variations in targeted next-generation sequencing data. BMC Bioinform. 2017;18. https://doi.org/10.1186/s12859-017-1566-3 .

Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast cancers. Cell. 2012;149:994–1007.

doi: 10.1016/j.cell.2012.04.023

Salcedo A, Tarabichi M, Espiritu SMG, Deshwar AG, David M, Wilson NM, et al. A community effort to create standards for evaluating tumor subclonal reconstruction. Nat Biotechnol. 2020;38:97–107.

doi: 10.1038/s41587-019-0364-z

Chen L, Chen JY, Huang YJ, Gu Y, Qiu J, Qian H, et al. The augmented R-loop is a unifying mechanism for myelodysplastic syndromes induced by high-risk splicing factor mutations. Mol Cell. 2018;69:412–25.e6.

doi: 10.1016/j.molcel.2017.12.029

Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400–4.

doi: 10.1038/s41586-018-0317-6

Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016;213:1479–96.

doi: 10.1084/jem.20151136

Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127:3410–23.

doi: 10.1182/blood-2015-11-679431

Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667–79.

doi: 10.1182/blood-2016-10-695940

Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062–9.

doi: 10.1182/blood-2014-05-578435

Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009;27:754–62.

doi: 10.1200/JCO.2008.18.2246

Hu Z, Ramos CEB, Medeiros LJ, Zhao C, Yin CC, Li S, et al. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis. Hum Pathol. 2019;85:290–8.

doi: 10.1016/j.humpath.2018.10.026

Cargo C, Cullen M, Taylor J, Short M, Glover P, Van Hoppe S, et al. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood. 2019;133:1325–34.

doi: 10.1182/blood-2018-08-867333

Cazzola M. Clonal monocytosis of clinical significance. Blood. 2019;133:1271–2.

doi: 10.1182/blood-2019-01-896084

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019;104:1935–49.

doi: 10.3324/haematol.2019.222059

Yoshimi A, Lin K-T, Wiseman DH, Rahman MA, Pastore A, Wang B, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. Nature. 2019. https://doi.org/10.1038/s41586-019-1618-0 .